{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:44:46Z","timestamp":1785703486366,"version":"3.56.0"},"reference-count":68,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National Institute of Health (NIH) National Institute on Minority Health and Health Disparities","award":["U54MD007582"],"award-info":[{"award-number":["U54MD007582"]}]},{"name":"National Cancer Institute (NCI) of the National Institutes of Health","award":["U54CA233396"],"award-info":[{"award-number":["U54CA233396"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Dysregulated epidermal growth factor receptor (EGFR) signaling is a key mechanism driving cancer progression and metastasis. Owing to its frequent overexpression in pancreatic cancer (PCa), EGFR has become a desirable molecular target for targeted therapies. XYZ-I-73 (N-(5-fluoro-2-oxo-1-(tetrahydrofuran-2-yl)-1,2-dihydropyrimidin-4-yl) dodecanamide), a structural analog of 5-fluorouracil (5-FU), has been previously synthesized and shown to exhibit cytotoxicity against PCa cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>XYZ-I-73 was entrapped in liposomes via thin-film hydration and subsequently conjugated to EGFR antibodies to produce an immunoliposome formulation- Ab-XYZ-I-73LnP (where \u2018Ab\u2019 denotes antibody-conjugated and \u2018LnP\u2019 denotes liposomal nanoparticle). In vitro efficacy was assessed by measuring cell viability and apoptosis in MiaPaCa-2 and PANC-1 cells, while pharmacokinetics and antitumor efficacy were determined in a cell line-derived xenograft (CDX) mouse model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ab-XYZ-I-73LnP exhibited a mean particle size of 143nm \u00b1 2.3, PDI (0.37), and zeta potential -46.2 \u00b1 1.3mV. In MiaPaCa-2 cells, Ab-XYZ-I-73LnP showed remarkably higher cytotoxicity than 5-FU in both 2D (IC\n                      <jats:sub>50<\/jats:sub>\n                      = 2.5 \u00b1 0.9\u03bcM vs 13.2 \u00b1 1.1\u03bcM) and 3D cultures (IC\n                      <jats:sub>50<\/jats:sub>\n                      = 8.1 \u00b1 1.1\u03bcM vs 26.7 \u00b1 1.1 \u03bcM). Similarly, in PANC-1 cells, Ab-XYZ-I-73LnP showed lower IC\n                      <jats:sub>50<\/jats:sub>\n                      values compared to 5-FU;2D (IC\n                      <jats:sub>50<\/jats:sub>\n                      = 2.9 \u00b11.1 \u03bcM vs 20.4\u00b11.2 \u03bcM), 3D (IC\n                      <jats:sub>50<\/jats:sub>\n                      = 12.9 \u00b1 0.6\u03bc\u039c vs 37.1\u00b10.9 \u03bcM). Pharmacokinetic analysis revealed a prolonged half-life for Ab-XYZ-I-73LnP compared with free 5-FU (t1\/2 = 1.62 \u00b1 0.03 h vs 0.49 \u00b1 0.01 h, p &lt; 0.001). There was about a 2-fold increase in the area under the curve (AUC) for Ab-XYZ-I-73LnP compared to 5-FU (AUC= 0.32 \u00b1 0.04\u00b5g\/(L*hr) vs 0.15 \u00b1 0.02\u00b5g\/(L*hr), p&lt;0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, the study supports the formulation of an immunoliposome of modified 5-FU, which may significantly enhance drug bioavailability and therapeutic potential for the treatment of PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338261468414","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:34:52Z","timestamp":1785436492000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6908-823X","authenticated-orcid":false,"given":"Esther","family":"Frimpong","sequence":"first","affiliation":[{"name":"Florida A&M University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raviteja","family":"Bulusu","sequence":"additional","affiliation":[{"name":"Florida A&M University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Okoro","sequence":"additional","affiliation":[{"name":"Florida A&M University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhu","sequence":"additional","affiliation":[{"name":"Florida A&M University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Ablordeppey","sequence":"additional","affiliation":[{"name":"Florida A&M University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[{"name":"University of Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saunjoo","family":"Yoon","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6905-5136","authenticated-orcid":false,"given":"Edward","family":"Agyare","sequence":"additional","affiliation":[{"name":"Florida A&M University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-0155"},{"key":"e_1_3_8_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00840-w"},{"issue":"1","key":"e_1_3_8_4_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. Cancer statistics. 2025;75(1):10-45.","journal-title":"Cancer statistics"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1166"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02499-y"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231164875"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2019.6190"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70035"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910843"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1039\/c0nr00132e"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/nano12244494"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2016.11.073"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.01.006"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0392-8"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01336-6"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00286"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27041372"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2018.1517747"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425240903579963"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.09.003"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.15.5744"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00846-z"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.05.008"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2015.06.003"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112748"},{"key":"e_1_3_8_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S226628"},{"key":"e_1_3_8_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12155"},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3021513"},{"key":"e_1_3_8_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00800"},{"key":"e_1_3_8_32_2","doi-asserted-by":"publisher","unstructured":"Damaraju VL Mowles D Wilson M Kuzma M Cass CE Sawyer MB. Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers. 2013;91(6):419-427. doi:10.1139\/BCB-2013-0041.","DOI":"10.1139\/BCB-2013-0041"},{"key":"e_1_3_8_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658636"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers2031717"},{"key":"e_1_3_8_35_2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8612"},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPS.2024.106754"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.10.096"},{"key":"e_1_3_8_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020554"},{"key":"e_1_3_8_39_2","first-page":"11","article-title":"The bicinchoninic acid (BCA) assay for protein quantitation","volume":"32","author":"Walker JM","year":"1994","unstructured":"Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation. Protein Protoc Handb. 1994;32:11-15. Published online.","journal-title":"Protein Protoc Handb"},{"key":"e_1_3_8_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-49320-5_2"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054288"},{"key":"e_1_3_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(90)90267-d"},{"key":"e_1_3_8_43_2","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200525161359"},{"key":"e_1_3_8_44_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389201023666220309154439"},{"key":"e_1_3_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2011.11.039"},{"key":"e_1_3_8_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12195-020-00616-1"},{"key":"e_1_3_8_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau7314"},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.15761\/icst.1000150"},{"key":"e_1_3_8_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep21648"},{"key":"e_1_3_8_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02633-z"},{"key":"e_1_3_8_51_2","doi-asserted-by":"publisher","DOI":"10.17226\/12910"},{"key":"e_1_3_8_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X20943823"},{"key":"e_1_3_8_53_2","doi-asserted-by":"publisher","DOI":"10.21037\/APC.2020.03.03"},{"issue":"1","key":"e_1_3_8_54_2","first-page":"e171","article-title":"Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse","volume":"2","author":"Udofot O","year":"2016","unstructured":"Udofot O, Affram K, Smith T, et al. Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. J Nat Sci. 2016;2(1):e171.","journal-title":"J Nat Sci"},{"key":"e_1_3_8_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/S12672-023-00733-Z"},{"key":"e_1_3_8_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2011.583372"},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00245"},{"key":"e_1_3_8_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2020.1831106"},{"key":"e_1_3_8_59_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S146315"},{"key":"e_1_3_8_60_2","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2017.1408114"},{"key":"e_1_3_8_61_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031813"},{"key":"e_1_3_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2018.10.006"},{"key":"e_1_3_8_63_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/209205"},{"key":"e_1_3_8_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00574-6"},{"key":"e_1_3_8_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00298.x"},{"key":"e_1_3_8_66_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1711"},{"key":"e_1_3_8_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-026-02110-z"},{"key":"e_1_3_8_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104594"},{"key":"e_1_3_8_69_2","first-page":"144","article-title":"Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small","volume":"16","author":"Daram A","year":"2024","unstructured":"Daram A, Sawant SS, Mehta DA, Sanhueza CA, Kunda NK. Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small. Cell Lung Cancer. 2024;16:144.","journal-title":"Cell Lung Cancer"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261468414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338261468414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338261468414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:44:47Z","timestamp":1785699887000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338261468414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"alternative-id":["10.1177\/15330338261468414"],"URL":"https:\/\/doi.org\/10.1177\/15330338261468414","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338261468414\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338261468414\/v2\/review1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"15330338261468414"}}